Efficacy of complementary treatment with autologous platelet concentrates and/or mesenchymal stem cells in chemical osteonecrosis of the jaw. Systematic review of the literature

Escobedo, M.F.; Junquera, S.; González, Carlos Pérez; Vasatyuk, S.; Gallego, Lorena; Barbeito, E.; Junquera, Luís

doi:10.1016/j.jormas.2021.01.015

Cited by 8 publications

(10 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There have been over 1000 clinical trials exists with MSCs over 25 years [ 44 ], and their numbers are growing day by day. MSCs are being studied for the treatment of fractures [ 45 , 46 ], arthritis [ 47 ], osteonecrosis of the jaw [ 48 , 49 , 50 ], graft-versus-host disease [ 51 ], Crohn’s disease [ 52 ], multiple sclerosis [ 53 ], stroke [ 54 ], myocardial infarction [ 55 ], liver cirrhosis [ 56 ], and chronic lung disease [ 57 ]. Furthermore, they have immunosuppressive functions, and many studies are underway to develop therapies that take advantage of this function.…”

Section: Mesenchymal Stem Cells (Mscs)mentioning

confidence: 99%

Role and Function of Mesenchymal Stem Cells on Fibroblast in Cutaneous Wound Healing

et al. 2022

View full text Add to dashboard Cite

Skin wounds often repair themselves completely over time; however, this is true only for healthy individuals. Although various studies are being conducted to improve wound-healing therapy outcomes, the mechanisms of wound healing and regeneration are not completely understood yet. In recent years, mesenchymal stem cells (MSCs) have been reported to contribute significantly to wound healing and regeneration. Understanding the function of MSCs will help to elucidate the fundamentals of wound healing. MSCs are multipotent stem cells that are used in regenerative medicine for their ability to self-renew and differentiate into bone, fat, and cartilage, with few ethical problems associated with cell harvesting. Additionally, they have anti-inflammatory and immunomodulatory properties and antifibrotic effects via paracrine signaling, and many studies have been conducted to use them to treat graft-versus-host disease, inflammatory bowel disease, and intractable cutaneous wounds. Many substances derived from MSCs are involved in the wound-healing process, and specific cascades and pathways have been elucidated. This review aims to explain the fundamental role of MSCs in wound healing and the effects of MSCs on fibroblasts.

show abstract

Section: Mesenchymal Stem Cells (Mscs)mentioning

confidence: 99%

Role and Function of Mesenchymal Stem Cells on Fibroblast in Cutaneous Wound Healing

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Another review also concluded that the application of APCs may be helpful in the treatment and prevention of MRONJ, because of their local immunomodulatory properties and possible promotion of angiogenesis and tissue healing by platelet factors [ 34 ]. Conversely, in a more recent paper by Escobedo et al, it was concluded that there were no sufficient scientific data to support the use of APCs for the treatment of established MRONJ lesions [ 35 ]. Despite extensive research on the role of APCs in MRONJ management, the experimental data seem to remain controversial due to high risk of bias of the studies and the need for further investigation still exists.…”

Section: Discussionmentioning

confidence: 99%

Promising results of surgical management of advanced medication related osteonecrosis of the jaws using adjunctive leukocyte and platelet rich fibrin

Özalp

Yıldırımyan²,

Öztürk

et al. 2021

BMC Oral Health

View full text Add to dashboard Cite

Background Leukocyte- and platelet-rich fibrin (L-PRF) is an autologous matrix scaffold which regulates inflammation by stimulating cytokines and growth factors that are involved in the immune response. L-PRF is suggested as a viable adjunctive method to surgical interventions due to its advantages on tissue healing. This study aims to retrospectively evaluate the adjunctive role of L-PRF in surgically treated medication-related osteonecrosis of the jaws (MRONJ) patients. Methods Between January 2012 and December 2020, patients with AAOMS stage II and III MRONJ lesions, who were treated surgically with adjunctive use of L-PRF in the authors’ institution were enrolled. Surgical interventions consisted of either marginal resection or sequestrectomy with peripheral ostectomy (SPO) or curettage and L-PRF application. Medical records of these patients were retrospectively reviewed and healing was assessed according to certain parameters including mucosal closure and presence of infection, exposed bone, fistula or radiologic markers of disease progression for a minimum of 12 months. Results Thirteen patients (7 women and 6 men) with an average age of 72.4 years (± 10.61, range 54–84) were included in the study, nine of whom had AAOMS stage III and four stage II MRONJ. Three patients had a marginal resection, nine patients had sequestrectomy with peripheral ostectomy (SPO) and one patient underwent a curettage procedure. All marginal resection and six SPO patients showed complete healing while four patients, who had SPO or curettage experienced incomplete healing. Mean follow up was 20.1 ± 18.29 months. Conclusion The use of L-PRF may be a favorable adjunctive option in the treatment of MRONJ owing to its favorable effects on tissue repair, ease of application, minimally invasive and cost-effective character and autogenous nature. Trial registration Retrospectively registered.

show abstract

“…The review also highlighted the potential benefits of adjuvant treatments like hyperbaric oxygen, ozone therapy, and lowintensity laser therapy when combined with conservative treatment, suggesting that these might lead to higher success rates and positive outcomes [10]. Additionally, the use of APCs like platelet rich fibrin and concentrated growth factor, derived from the patient's blood, showed significant improvements in mucosal healing, down-staging, and low relapse rates due to their ability to release high quantities of growth factors that stimulate bone regeneration and tissue healing [8,9].…”

Section: Treatmentmentioning

confidence: 99%

“…APCs have emerged as a notable advancement in the management of MRONJ, offering promising results in mitigating the onset of MRONJ and fostering rapid epithelialization [8,9]. These concentrates, enriched with growth factors, are instrumental in modulating inflammation and expediting the immune response, crucial factors in the healing process for patients undergoing BP treatment.…”

Section: Apcsmentioning

confidence: 99%

“…Treatment strategies for MRONJ are diverse, ranging from conservative symptom management and infection control to more advanced surgical interventions, depending on the condition's severity and the patient's individual needs [1,2]. The potential of emerging therapies like autologous platelet concentrates (APCs), mesenchymal stem cells (MSCs), and laser therapy is recognized [8,9]. However, a detailed discussion of these therapies is reserved for subsequent sections to avoid redundancy and ensure a focused discourse [10].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Unveiling Medication-Related Osteonecrosis of the Jaw: A Rapid Review of Etiology, Drug Holidays, and Treatment Strategies

Oh,

Kim

2024

Applied Sciences

View full text Add to dashboard Cite

This rapid review critically evaluates recent advancements in the management of medication-related osteonecrosis of the jaw (MRONJ) from 2022 to 2023, employing a specific article selection protocol to focus on the latest literature. Initially screening 262 articles and ultimately selecting 22 based on their relevance and uniqueness, the process involved meticulous screening, methodological evaluation, and data extraction by the authors. The findings, organized into epidemiology, treatment effectiveness, and drug holidays, are synthesized following rapid review guidelines. The review addresses the risk of MRONJ associated with tooth extraction in patients undergoing antiresorptive medication therapy, such as bisphosphonates (BPs) and denosumab (DS), and evaluates the effectiveness of drug holidays in reducing this risk. Recent studies suggest that drug holidays may not effectively mitigate MRONJ risks as previously believed. Furthermore, it highlights that conservative treatment can benefit asymptomatic early-stage MRONJ patients, whereas surgical intervention is more effective for those in advanced stages. Ultimately, this review synthesizes current findings to enhance clinical practice, suggesting that while drug holidays may not significantly reduce MRONJ risks, treatment strategies should be tailored, ranging from conservative approaches in early stages to surgical interventions in advanced stages, thereby guiding evidence-based clinical decisions.

show abstract

Efficacy of complementary treatment with autologous platelet concentrates and/or mesenchymal stem cells in chemical osteonecrosis of the jaw. Systematic review of the literature

Cited by 8 publications

References 44 publications

Role and Function of Mesenchymal Stem Cells on Fibroblast in Cutaneous Wound Healing

Role and Function of Mesenchymal Stem Cells on Fibroblast in Cutaneous Wound Healing

Promising results of surgical management of advanced medication related osteonecrosis of the jaws using adjunctive leukocyte and platelet rich fibrin

Unveiling Medication-Related Osteonecrosis of the Jaw: A Rapid Review of Etiology, Drug Holidays, and Treatment Strategies

Contact Info

Product

Resources

About